Aura Biosciences Inc (AURA) 13F Filings: Institutional Buyers & Sellers (Q2 2026)

On August 11, 2026, Aura Biosciences issued a press release announcing its financial results for the quarter ended June 30, 2026. This 8-K includes that release as Exhibit 99.1 under Item 2.02, which is furnished but not considered "filed" for SEC liability purposes. The filing also lists other items (2.05, 5.02, 8.01, 9.01), but the excerpt doesn't include details on those, so this summary only covers the earnings release.

This 8-K from Aura Biosciences reports the results of a special shareholder meeting held on August 5, 2026. Shareholders approved two proposals: increasing the company's authorized common stock from 150 million to 500 million shares, and approving Amendment No. 1 to the company's 2021 Stock Option and Incentive Plan. The share authorization passed with about 63.0 million votes for and 26.5 million against; the incentive plan amendment passed with about 46.4 million votes for, 27.4 million against, and 15.7 million broker non-votes. No other items were voted on.

Aura Biosciences expanded its board from six to seven members on July 3, 2026, appointing Jeremy Bender as a new Class II director effective July 7. Bender also joined the Compensation and Nominating/Corporate Governance Committees. As an independent director, he received an initial stock option grant for 60,000 shares and 30,000 restricted stock units, vesting over three years. The company also disclosed its updated non-employee director compensation policy, with higher cash retainers and increased equity awards compared to the previous version. Bender is eligible for the same cash compensation as other non-employee directors under this policy.